KLOW
A four-peptide stack adding KPV, studied for inflammatory signaling, to GHK-Cu, BPC-157 and TB-500. Each peptide has limited human evidence, and we show you what exists for every one.
How it is offered
Priced With Your Plan
Pricing
Your clinician sets the plan. Pricing is shown before you authorize any charge.
Peptide stacks require a written prescription from a licensed clinician and are prepared by a licensed pharmacy for an individual patient. The compounds are not FDA-approved or evaluated for safety, effectiveness or quality, and they have not been studied together in controlled human trials. Evidence standards.
Start Your Assessment →What Is KLOW?
KLOW is a peptide stack: GHK-Cu, BPC-157, TB-500 and KPV together, used for repair and inflammation.
Each peptide has limited human evidence on its own, and the combination has almost none. We lay out what the published research does and does not show, peptide by peptide.
Good to Know
- Prescribed only after a clinician reviews your history.
- Dose and course are set by your clinician, not by you.
- Results vary, and we do not promise outcomes.
4 Peptides
What Is in It
Skin and tissue remodeling
GHK-Cu
A copper-binding tripeptide found naturally in human plasma. Decades of cell and animal research on tissue repair and gene expression. The human literature is thin: small trials, mostly of facial creams.
On FDA's Category 1 list except injectable routes.
Repair signaling
BPC-157
A 2025 systematic review found 36 studies, 35 of them preclinical. Animal work reports better tendon, ligament, muscle and bone healing. No clinical safety data were found.
On FDA's Category 2 safety-risk page.
Cell migration and tissue repair
TB-500
A synthetic fragment related to thymosin beta-4. Most research is on full-length thymosin beta-4 in cells and animals, and in people mainly in eye and skin-wound settings. A 2026 review found only one study of TB-500 itself.
On FDA's Category 2 safety-risk page.
Inflammatory signaling
KPV
A three-amino-acid fragment (Lys-Pro-Val) studied in cell and mouse models of intestinal inflammation, where it reduced inflammatory signaling. There are no human trials.
On FDA's Category 2 safety-risk page.
Who It Is For
Eligibility
Competitive Athletes
BPC-157 and TB-500 are both on the WADA Prohibited List. A prescription does not establish sporting eligibility, so we ask about anti-doping rules before presenting any option.
Often a Good Fit If
- ✓A persistent repair or inflammation concern that has not resolved with standard care
- ✓Comfortable with very limited human safety data and almost no data on the combination
- ✓Willing to complete a baseline visit and a defined course
- ✓Open to stopping if there is no measurable or subjective benefit
Not Prescribed If
- —Pregnancy, breastfeeding, or actively trying to conceive
- —Active or recent cancer diagnosis, or a history your clinician judges to carry risk
- —Wilson disease or any condition affecting copper handling, for stacks that contain a copper peptide
- —Expecting a guaranteed or fast outcome rather than a considered trial
- —Subject to anti-doping rules that prohibit these compounds
Read Before You Decide
Key Risks, Stated Plainly
Combining peptides multiplies the unknowns. For each compound alone, human safety data are limited. For the combinations there are almost none. Reported effects in the limited data include injection-site irritation, headache and nausea, and long-term effects are not known. Several of these peptides are studied for promoting new blood vessel growth and cell migration, which is a theoretical reason for caution in anyone with a cancer history.
Contact care the same day for
Significant swelling or pain at an injection site, signs of allergic reaction, chest pain, shortness of breath, or any new or unexplained symptom during a course.
What Is Measured
Baseline Function and Symptoms
A baseline you rate at the start, so a change can be compared with it.
Injection-Site Tolerance
Reviewed early, when most reactions appear.
Training or Activity Load
What you can do compared with what you could before.
Anti-Doping Check
Competitive athletes are screened against current sport rules first.
Course Endpoint
A scheduled reassessment against your original goal, with a written decision.
A Clearer Path Forward
How Clinicians Review Your Response
You and Your Clinician Look at the Same Data
Symptoms you report, laboratory results and, if you connect one, wearable trends are reviewed together before any change.
A Physician-Led Review Every 90 Days
Included in your monthly price. Your clinician decides whether to continue, adjust the dose, change course or stop.
Clinical Judgment Decides
Measurements inform the decision. They do not make it, and no dashboard changes your dose on its own.
Your Care Sequence
01
Questionnaire
Share your goals, history and any sport or work rules in about ten minutes. No card required.
02
Video Visit
Your clinician reviews your history and medications, explains the evidence plainly, and decides whether a stack is right for you.
03
Delivery
If prescribed, medication ships from a licensed pharmacy with supplies and written instructions.
04
Reassessment
A scheduled review decides whether to stop, extend or change course. Stacks are not renewed by default.
Common Questions About KLOW
What Is the KLOW Stack?+
A combination of four peptides, GHK-Cu, BPC-157, TB-500 and KPV, marketed for repair and inflammation. The name comes from the peptide marketplace, not from any clinical standard.
How Does It Differ From GLOW?+
It adds KPV, a compound studied for inflammatory signaling in cells and mice. A fourth compound adds another set of unknowns, and there is no human evidence that it improves on GLOW.
Has This Combination Been Studied in People?+
Almost not. The only human report we found that includes BPC-157 together with thymosin beta-4 is a small retrospective chart review of knee injections, in which 4 of 16 patients received both and most self-reported relief, with no control group. Each compound has limited human data on its own. We say this plainly because the combination is sold elsewhere with much bolder claims.
What Does the Research Actually Show?+
Mostly laboratory and animal work. A 2025 systematic review of BPC-157 found 36 studies, 35 of them preclinical. A 2026 review of thymosin beta-4 and TB-500 found 80 studies, only one of which evaluated TB-500 directly. The GHK-Cu human literature is small trials, mostly of facial creams.
Why Do People Combine Peptides?+
The idea is that each compound has a different proposed job, so together they might cover more ground. That is a hypothesis. Combining compounds also adds interactions and unknowns, which is why we do not treat a stack as better than a single, well-understood option.
Can I Use It If I Compete in Sport?+
Probably not. BPC-157 and TB-500 are on the WADA Prohibited List, and a prescription does not change that.
Still unsure? Message the care team before you join. No account needed.
Published Research
What the Published Science Shows
0
Human trials of KPV. Its published evidence is in cell lines and mouse models of intestinal inflammation.
35 of 36
Studies in the 2025 systematic review of BPC-157 that were preclinical.
1 of 80
Studies in a 2026 review of thymosin beta-4 that directly evaluated TB-500 itself.
Figures come from the cited trials and reviews. They describe published research, not a forecast for any one person, and not a study of compounded formulations.
The Mechanism
The Proposed Mechanism
Tissue Remodeling
GHK-Cu is proposed to influence collagen, elastin and extracellular-matrix signaling.
Repair Signaling
BPC-157 is proposed to support blood vessel growth toward injured tissue, from animal data.
Cell Migration
Thymosin beta-4 binds actin, a protein that helps cells move to a repair site. TB-500 is a related fragment.
Inflammatory Signaling
KPV reduced inflammatory signaling and colitis in cell and mouse experiments. It has not been tested in people.
For Readers Who Want More
Deeper Evidence
What We Can and Cannot Tell YouEvidence and regulatory status+
What the Evidence Supports
Plausible mechanisms in laboratory and animal work, and small human trials of copper peptide on skin appearance.
What It Does Not (Yet)
No controlled human trials of the combination and no established efficacy for any component by injection. Two of the four are on the WADA Prohibited List.
Badge definitions and FDA category sourcing are on the Science page.
Illustrative Course StructureFinal dose set by your clinician+
Illustrative only and not a prescription. Doses and ratios are set by your clinician and the compounding pharmacy.
| Phase | Approach | Duration | What We Watch |
|---|---|---|---|
| Baseline | Visit and symptom baseline | Before starting | Symptoms, function |
| Course | Clinician-set dose, held at the tolerated level | Defined by your clinician | Injection sites, symptoms |
| Reassessment | Extend, stop or change course | At the scheduled review | Whether the goal was met |
How the Stacks DifferWhat “compounded” means+
| Stack | Peptides |
|---|---|
| Wolverine | BPC-157, TB-500 |
| GLOW | GHK-Cu, BPC-157, TB-500 |
| KLOW | GHK-Cu, BPC-157, TB-500, KPV |
More peptides means more unknowns. None of these combinations has been studied together in controlled human trials.
Selected Studies
Dalmasso et al., Gastroenterology, 2008 (PMID 18061177)
In human cell lines and in two mouse models of colitis, KPV reduced inflammatory signaling and the incidence of colitis. These were laboratory and animal experiments, not human trials.
Read the Source ↗Vasireddi et al., HSS Journal, 2025 (systematic review of BPC-157)
Of 36 studies, 35 were preclinical and 1 was clinical. Animal work reports better muscle, tendon, ligament and bone healing outcomes. No clinical safety data were found, and the authors advise caution and counseling for athletes.
Read the Source ↗Pickart and Margolina, International Journal of Molecular Sciences, 2018 (review of GHK-Cu)
Reviews decades of mostly laboratory work on the GHK peptide: effects on collagen and elastin synthesis, blood vessel and nerve outgrowth, and gene expression. It is a review, not a clinical trial.
Read the Source ↗Najafi et al., 2026 (PMID 42787770), systematic review of GHK-Cu
After screening 1,247 records, 64 were synthesized. The authors conclude the preclinical evidence is deep but the human literature is thin and fragmented, with small trials mostly of facial creams.
Read the Source ↗McGuire et al., 2026 (scoping review of thymosin beta-4 and TB-500; preprint, not peer-reviewed)
Of 80 included studies, most were in vitro or animal, most evaluated thymosin beta-4 rather than TB-500, and only one directly evaluated TB-500. Human evidence was concentrated in eye and skin-wound settings, with little for tendon, ligament or muscle.
Read the Source ↗Start Your Assessment for Recovery Options
Ten minutes, no card, reviewed by a clinician.